Ulobetasol propionate
Pharmaceutical drug
- D07AC21 (WHO)
- CA: ℞-only[1]
- US: ℞-only
- [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-Chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
- 66852-54-8
- 6918178
- DB00596
- 91A0K1TY3Z
- ChEMBL1200908
- ChEMBL1876307
- DTXSID6046636
- Interactive image
- CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)CCl
InChI
- InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15-,16-,18-,19-,22-,23-,24-,25-/m0/s1
- Key:BDSYKGHYMJNPAB-LICBFIPMSA-N
Ulobetasol propionate, also known as halobetasol propionate and sold under the brand name Ultravate among others, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester.
It was patented in 1975 and approved for medical use in 1990.[2][3]
References
- ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
- ^ "Ultravate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 29 April 2020.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 487. ISBN 9783527607495.
- v
- t
- e
- See also
- Receptor/signaling modulators
- Glucocorticoids and antiglucocorticoids
- Mineralocorticoid receptor modulators
- List of corticosteroids
This article about a steroid is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e